Victoria Creamer Sells 4,179 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Victoria Creamer sold 4,179 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the transaction, the executive vice president directly owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Charles River Laboratories International Stock Performance

NYSE:CRL traded up $8.85 during mid-day trading on Monday, reaching $276.34. The stock had a trading volume of 1,025,309 shares, compared to its average volume of 924,952. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $277.07. The business has a 50 day simple moving average of $214.85 and a 200 day simple moving average of $189.04. The firm has a market capitalization of $13.19 billion, a price-to-earnings ratio of -56.98, a PEG ratio of 2.77 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on CRL shares. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $180.00 to $310.00 in a research report on Thursday. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research note on Monday, July 20th. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday. Finally, Morgan Stanley raised their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $255.65.

Hedge Funds Weigh In On Charles River Laboratories International

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Charles River Laboratories International by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after purchasing an additional 47,432 shares in the last quarter. Invesco Ltd. raised its stake in shares of Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after buying an additional 1,446,972 shares during the last quarter. State Street Corp raised its stake in shares of Charles River Laboratories International by 2.2% during the 4th quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after buying an additional 40,535 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after buying an additional 210,260 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Charles River Laboratories International by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after acquiring an additional 9,756 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.